[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaso-occlusive-pain-episode-in-sickle-cell-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaso-occlusive-pain-episode-in-sickle-cell-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,80,112,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053379","phase-3-lidocaine-for-opioid-sparing-in-vaso-occlusive-crisis-of-sickle-cell-disease-100053379",false,"NCT07274254","Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease","LidoVOC","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Known sickle cell disease with an SS, SC, Sβ, or Sβ+ genotype\n* Patient admitted to the Intensive Care Unit for Vaso-Occlusive Crisis and\u002For ACS as the main reason for admission:\n\n  * Vaso-Occlusive Crisis defined by acute pain or tenderness, affecting at least one part of the body, including limbs, ribs, sternum, head (skull), spine, and\u002For pelvis, not attributable to other causes\n  * Acute Chest Syndrome defined by the association of clinical respiratory sign(s): dyspnea and\u002For chest pain and\u002For auscultatory abnormality (crepitants and\u002For bronchial breathing) with a new pulmonary infiltrate on chest X-ray, thoracic CT-scan, or lung ultrasound.\n* Treatment with parenteral morphine or oxycodone started less than 72 hours prior to inclusion\n* Patient or next of kin informed about the study and having consented to the participation of the patient in the study. If patient is no competent and no next of kin can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the Intensive Care Unit physician, in compliance with French law.\n* French speaking\n* Patient with health care insurance\n\nExclusion Criteria:\n\n* Pregnant women or nursing mothers; Women of child bearing potential will be tested for pregnancy before inclusion\n* Patients under guardianship, curatorship or under legal protection\n* Prisoners or subjects who are involuntarily incarcerated\n* Sickle Cell Disease acute complication other than Vaso-Occlusive Crisis or Acute Chest Syndrome as the main reason for admission:\n\npriapism, stroke, acute splenic sequestration, acute hepatic sequestration, bone marrow necrosis…\n\n* Patients wearing a lidocaine-medicated plaster at the time of screening for inclusion\n* Known or assumed hypersensitivity to lidocaine hydrochloride, other local anaesthetics (e.g., bupivacaine or ropivacaine) or an excipient\n* Patients treated with anti-arhythmic drugs known to induce torsade de pointe.\n* Patients on chronic or occasional treatment with drugs that interact with the 3A cytochrome isoenzymes (CYP3A) and\u002For 1A2 cytochrome isoenzymes (CYP1A2)\n* Patients with recurrent porphyria, porphyria in remission, or known asymptomatic carriage of gene mutations responsible for porphyria\n* Epileptic patients\n* Hypovolemic shock or shock of other cause at screening for inclusion\n* Known atrioventricular block, QT prolongation or other heart conduction disorder or heart failure\n* Chronic respiratory failure with long term non invasive ventilation (excluding Continuous Positive Air way pressure), or long term oxygen therapy at home\n* Acute Respiratory Distress Syndrome according to The 2012 Berlin definition\n* Acute or Chronic liver failure with MELD \\> 19 according to CKD-EPI\n* Acute or Chronic kidney failure with clearance \\\u003C30mL\u002Fmin\u002Fm2\n* Body weight \\\u003C40kg and \\>120kg\n* Prior inclusion in the study in the last 3 months\n* Patient under invasive mechanical ventilation\n* Altered consciousness with Glasgow coma scale \\\u003C13","ALL","18 Years",{"count":19,"type":20},104,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.",[26],"Vaso-Occlusive Pain Episode in Sickle Cell Disease",[28,29,30,31,32,33,34,35],"Sickle Cell disease","Sickle Cell Syndrome","Vaso-occlusive crisis","Acute Chest Syndrome","Painful crisis","Pain management","Opioid sparing","Lidocaine","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2026-07-03",{"date":44,"type":20},"2028-08-03",{"name":46,"class":47},"Nantes University Hospital","OTHER",11,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100567269","phase-4-clinical-and-biomarker-effects-of-depot-medroxyprogesterone-acetate-in-females-with-sickle-cell-disease-100567269","NCT06665997","Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease","SCD Depo","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Female, aged 18-50 years old\n3. Diagnosis of sickle cell disease (SS, SB0,SB+,SC)\n4. Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months\n5. At least 1 and no more than 10 medical presentations (e.g. hospitalization, emergencyroom visit, outpatient infusion visit) for vaso-occlusive pain during the past year, unless approved by study PI Andrea Roe\n6. Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month since last use of all hormonal contraception, and 4 months since most recent administration of depot medroxyprogesterone, is required prior to enrollment in the study.\n7. Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days.\n8. Stable dose of hydroxyurea and other sickle cell-related medications for the past 6 months\n9. Access to a device with text-messaging capability\n10. Must be able to read and understand English\n11. Willing to comply with study procedures\n\nExclusion Criteria:\n\n1. Chronic inflammatory conditions, such as lupus or inflammatory bowel disease\n2. History of VTE or stroke\n3. Current use of crizanlizumab, voxelotor, or chronic transfusion therapy, including simple transfusion and red cell exchange transfusion, history of hematopoietic stem cell transplantation\n4. Current use of hormonal contraception or the copper intrauterine device\n5. Current pregnancy or pregnancy within the last 6 months\n6. Current lactation\n7. Polycystic ovary syndrome or irregular periods\n8. Blood pressure \\>= 160 systolic or \\>=100 diastolic at screening visit\n9. Has a history or current evidence of any condition, therapy, or other circumstance that in the opinion of the investigator exposes the participant to risk through participating in the trial, may confound the results of the trial, or could interfere with participation for the full duration of the trial.","FEMALE","50 Years",{"count":59,"type":20},65,[61],"PHASE4","This research is being conducted to see if using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain experienced by women with sickle cell disease.\n\nParticipants in this study will be adult women with sickle cell disease who regularly experience sickle cell pain. They will complete a 3-month \"baseline \"with no use of hormonal contraception, and then a 3-month follow-up after receiving an injection of Depo-Provera. Participants will complete 6 to 7 in-person visits with a urine pregnancy test, blood draw, and surveys, as well as complete remote weekly surveys and monthly home pregnancy tests.",[64,26],"Sickle Cell Disease (SCD)",[66,67,68,69],"Sickle Cell Disease","Depot Medroxyprogesterone Acetate (Depo-Provera)","Contraception","Vaso-Occlusive Pain","2026-05-26",{"date":72,"type":40},"2026-05-28",{"date":74,"type":40},"2025-06-26",{"date":76,"type":20},"2028-07-31",{"name":78,"class":47},"University of Pennsylvania",2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100621315","phase-2-sub-dissociative-dose-ketamine-in-treatment-of-vaso-occlusive-pain-event-in-children-and-young-adults-100621315","NCT07369024","Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults","Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults: A Randomized Control Trial","Inclusion Criteria:\n\n* Between the ages 5-20 years\n* Diagnosed sickle cell disease. Homozygous (HbSS) or heterozygous (HbSC, HbSBetaThal Plus or Zero) will be included.\n* Presenting with VOE pain, requiring IV pain medication.\n* First dose of analgesic medication is given before patient approached for participation in the study.\n* Primary language is English or Spanish\n* Adult individual or parent\u002Flegal guardian is able and willing to provide informed consent. For individuals 7 to 17 years of age, assent must also be provided when cognitively possible.\n\nExclusion Criteria:\n\n* Sickle cell trait only\n* Patients whose primary language is other than English or Spanish\n* Pain attributed to causes other than VOE\n* Not requiring IV for pain treatment\n* No analgesic (e.g. opiate) is given before approach for study participation due to any reason, including problem with IV access.\n* Oxygen saturation \\\u003C 90% on room air\n* History of prior adverse reaction to ketamine\n* History of hypertension - Patients with active\u002Funcontrolled hypertension defined as systolic 140 mmHg over diastolic of 90 mmHg will be excluded from participation in the study. If hypertension is controlled and at the time of enrollment, systolic and diastolic thresholds of 140 mmHg and 90 mmHg respectively are not exceeded, patient may be included in the study\n* History of significant or uncontrolled cardiovascular disease, liver disease, kidney disease, and thyroid disease\n* Patients with evidence of increased intracranial pressure\n* Patients with elevated intraocular pressure\n* Patients with acute mania or history of bipolar disorder with manic episodes, history of hallucinations or paranoia secondary to previously diagnosed psychiatric condition\n* Pregnant or potentially pregnant patients per patient report. All patients of childbearing potential will undergo pregnancy testing prior to enrollment (as part of clinical care), and if positive, will be excluded.\n* Elevated liver enzymes (alkaline phosphatase, ALT, AST, bilirubin) as sign of hepatic disfunction if the laboratory results are available prior to study participation\n* Patients who appear intoxicated on any substance.\n* Patients who are wards of the state or prisoners as defined by DHS\n* Patients who are not deemed to be competent to provide consent or assent.","5 Years","20 Years",{"count":90,"type":20},120,[92],"PHASE2","The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.",[66,26,95,96,97],"Ketamine Infusion","Pain Management","Vaso-Occlusive Crises",[66,99,100,101],"Vaso-Occlusive Pain Episode","Sub-Dissociative Ketamine","Pediatric Pain Management","2026-03-05",{"date":104,"type":40},"2026-03-09",{"date":106,"type":20},"2026-04-01",{"date":108,"type":20},"2028-04-30",{"name":110,"class":47},"Mohsen Saidinejad",1,{"id":113,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":24,"conditions":116,"keywords":117,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":48},"100614027",{"count":19,"type":20},[23],[26],[28,29,30,31,32,33,34,35],"NOT_YET_RECRUITING","2025-12-18",{"date":121,"type":40},"2025-12-26",{"date":123,"type":20},"2026-03-01",{"date":125,"type":20},"2028-04-01",{"name":46,"class":47},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":111},"100530234","virtual-reality-devices-as-an-adjunct-to-usual-care-for-patients-with-sickle-cell-disease-experiencing-vaso-occlusive-crises-100530234","NCT06184126","Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises","Pilot Study to Investigate the Use of Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises","Inclusion Criteria:\n\n* Adult (age \\> 18 years) emergency department patient\n* History of sickle cell disease\n* Presenting to the emergency department due to acute pain related to sickle cell disease thought to be due to vaso-occlusive crisis\n\nExclusion Criteria:\n\n* Prior enrollment in this study\n* Presenting with a chief complaint suggestive of a complicated crisis (such as concern for acute chest syndrome, splenic sequestration, hepatic sequestration, pulmonary embolism) as determined by the clinical care provider\n* Not being treated with intravenous opioids for the vaso-occlusive crisis\n* Patients who lack the capacity to provide informed consent\n* Medical history of seizures or known intolerance to virtual reality\n* Disabilities like vision and hearing defects etc. that preclude the use of a head mounted virtual reality device.\n* Known to be pregnant\n* Incarcerated at the time of evaluation\n* Over the age of 89 years old",{"count":135,"type":20},30,[137],"NA","This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.",[66,140,141],"Vaso-occlusive Pain Episode in Sickle Cell Disease","Acute Pain","2025-12-17",{"date":144,"type":40},"2025-12-24",{"date":146,"type":40},"2024-11-01",{"date":148,"type":20},"2026-12-31",{"name":150,"class":47},"University of Maryland, Baltimore"]